日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID.

一种新型PLpro抑制剂改善了新冠肺炎长期症状的临床前模型的结果

M Bader Stefanie, Calleja Dale J, Devine Shane M, Kuchel Nathan W, Lu Bernadine G C, Wu Xinyu, Birkinshaw Richard W, Bhandari Reet, Loi Katie, Volpe Rohan, Khakham Yelena, Au Amanda E, Blackmore Timothy R, Mackiewicz Liana, Dayton Merle, Schaefer Jan, Scherer Lena, Stock Angus T, Cooney James P, Schoffer Kael, Maluenda Ana, Kleeman Elizabeth A, Davidson Kathryn C, Allison Cody C, Ebert Gregor, Chen Gong, Katneni Kasiram, Klemm Theresa A, Nachbur Ueli, Georgy Smitha Rose, Czabotar Peter E, Hannan Anthony J, Putoczki Tracy L, Tanzer Maria, Pellegrini Marc, Lechtenberg Bernhard C, Charman Susan A, Call Melissa J, Mitchell Jeffrey P, Lowes Kym N, Lessene Guillaume, Doerflinger Marcel, Komander David

Re-appraising assays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic agents selectively targeting pro-survival BCL2 proteins.

重新评估在透化血癌细胞上测试维奈托克或其他 BH3 模拟剂的试验,这些药物选择性地靶向促生存 BCL2 蛋白

Gong Jia-Nan, Djajawi Tirta M, Moujalled Donia M, Pomilio Giovanna, Khong Tiffany, Zhang Li-Ping, Fedele Pasquale L, Low Michael S, Anderson Mary Ann, Riffkin Christopher D, White Christine A, Lan Ping, Lessene Guillaume, Herold Marco J, Strasser Andreas, Spencer Andrew, Grigoriadis George, Wei Andrew H, van Delft Mark F, Roberts Andrew W, Huang David C S

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia.

BAX 基因的获得性突变可使急性髓系白血病对 BH3 模拟疗法产生耐药性

Moujalled Donia M, Brown Fiona C, Chua Chong Chyn, Dengler Michael A, Pomilio Giovanna, Anstee Natasha S, Litalien Veronique, Thompson Ella, Morley Thomas, MacRaild Sarah, Tiong Ing S, Morris Rhiannon, Dun Karen, Zordan Adrian, Shah Jaynish, Banquet Sebastien, Halilovic Ensar, Morris Erick, Herold Marco J, Lessene Guillaume, Adams Jerry M, Huang David C S, Roberts Andrew W, Blombery Piers, Wei Andrew H

Removal of BFL-1 sensitises some melanoma cells to killing by BH3 mimetic drugs

去除BFL-1可使某些黑色素瘤细胞对BH3模拟药物的杀伤作用更加敏感。

Gangoda, Lahiru; Schenk, Robyn L; Tai, Lin; Szeto, Pacman; Cheung, Jen G; Strasser, Andreas; Lessene, Guillaume; Shackleton, Mark; Herold, Marco J

Defining the susceptibility of colorectal cancers to BH3-mimetic compounds

确定结直肠癌对BH3模拟化合物的敏感性

Luo, Ming-Jie; Palmieri, Michelle; Riffkin, Chris D; Sakthianandeswaren, Anuratha; Djajawi, Tirta Mario; Hirokawa, Yumiko; Shuttleworth, Victoria; Segal, David H; White, Christine A; Nhu, Duong; Lessene, Guillaume; Lee, Margaret; Gibbs, Peter; Huang, David C S; Sieber, Oliver M; Gong, Jia-Nan